Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
573 stopped studies mapped to Multiple Myeloma and descendants · 91% state a reason
Over the 573 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04150965 | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT | Phase 1 / Phase 2 | terminated | Nov 5, 2019 | Multiple Myeloma Research Consortium | Pharmaceutical support has been discontinued. | Other (stated, no rule matched) |
| NCT03180853 | Multiple Myeloma Patient Registry | — | terminated | Jun 8, 2017 | Janssen Scientific Affairs, LLC | Completion of study in orig timeframe not feasible considering evolving treatments for MM in US. | Other (stated, no rule matched) |
| NCT03061305 | Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors | — | terminated | Feb 23, 2017 | Strata Oncology | Sponsor's discretion to termination due to business decision. | Sponsor / business decision |
| NCT06411301 | A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory…(AcTRESS) | Phase 1 | withdrawn | May 13, 2024 | Jules Bordet Institute | Sponsor decision | Sponsor / business decision |
| NCT05117008 | Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed…(EMBRACE) | Phase 2 | terminated | Nov 11, 2021 | Medical College of Wisconsin | Low enrollment. | Enrollment / accrual |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | Phase 1 | terminated | May 14, 2021 | Lava Therapeutics | The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive… | Safety / toxicity |
| NCT05427812 | Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 22, 2022 | Ichnos Sciences SA | Business decision | Sponsor / business decision |
| NCT05191472 | Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After… | Phase 2 | terminated | Jan 13, 2022 | Alfred Chung, MD | Slow Accrual | Enrollment / accrual |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory… | Phase 1 | terminated | Jan 28, 2020 | CRISPR Therapeutics AG | Patients to be followed up in the CRSP-ONC-LTF study | Other (stated, no rule matched) |
| NCT03582033 | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma | Phase 1 | terminated | Jul 10, 2018 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05276622 | Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)(PaCE-MM) | — | terminated | Mar 11, 2022 | UNC Lineberger Comprehensive Cancer Center | Investigator left the institution. | Investigator |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT06050512 | Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | Phase 1 / Phase 2 | withdrawn | Sep 22, 2023 | Kathleen Dorritie | Closure of trial per BMS | Other (stated, no rule matched) |
| NCT03804424 | 64Cu-LLP2A for Imaging Multiple Myeloma | Early Phase 1 | terminated | Jan 15, 2019 | Washington University School of Medicine | Drug formulation changed, opening new trial | Other (stated, no rule matched) |
| NCT05113342 | Descartes-25 in Relapsed/Refractory Multiple Myeloma | Phase 1 | terminated | Nov 9, 2021 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated. | Enrollment / accrual |
| NCT03870451 | Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma | N/A | terminated | Mar 12, 2019 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT05289492 | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 21, 2022 | iTeos Therapeutics | Company operational decision. Decision to stop study is not due to safety or efficacy concerns | Safety / toxicity |
| NCT03710915 | A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma | Phase 1 | terminated | Oct 18, 2018 | HitGen Inc. | Company decision | Sponsor / business decision |
| NCT04271930 | Effect of Sleep Quality on Hematopoietic Cell Transplant Patient Outcomes | N/A | terminated | Feb 17, 2020 | Medical College of Wisconsin | This study terminated early due to lack of participant retention | Other (stated, no rule matched) |
| NCT04816526 | Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma… | Phase 2 | terminated | Mar 25, 2021 | Cartesian Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | — | withdrawn | Nov 24, 2014 | Wake Forest University Health Sciences | No patients enrolled | Enrollment / accrual |
| NCT05971056 | Providing Cancer Care Closer to Home for Patients With Multiple Myeloma | N/A | terminated | Aug 2, 2023 | Washington University School of Medicine | Insufficient funding | Funding |
| NCT02099539 | QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 31, 2014 | Altor BioScience | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT02002598 | Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma | Phase 1 / Phase 2 | terminated | Dec 6, 2013 | Suzanne Lentzsch, MD | Slow accrual and loss of funding | Enrollment / accrual |
| NCT02978235 | A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple… | Phase 1 | terminated | Nov 30, 2016 | Taiho Oncology, Inc. | The trial was put on Clinical Hold and subsequently terminated prior to Phase 2 due to cases of… | Other (stated, no rule matched) |
| NCT03000634 | 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation… | Phase 2 | withdrawn | Dec 22, 2016 | University of Arkansas | Study was not and will not be initiated due to lack of funding. | Funding |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801),… | Phase 1 | terminated | May 21, 2018 | Pfizer | A business decision was made by Pfizer to terminate the study. Termination was not due to any… | Safety / toxicity |
| NCT04036461 | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and… | Phase 1 | terminated | Jul 29, 2019 | Celgene | Slow accrual | Enrollment / accrual |
| NCT04545333 | The clonoSEQ® Watch Registry | — | terminated | Sep 11, 2020 | Adaptive Biotechnologies | Sufficient data collected. | Other (stated, no rule matched) |
| NCT05908396 | Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | terminated | Jun 18, 2023 | IGM Biosciences, Inc. | Company Decision | Sponsor / business decision |
| NCT05050305 | Marizomib Central Nervous System (CNS) | Phase 2 | withdrawn | Sep 20, 2021 | Dana-Farber Cancer Institute | Study support withdrawn | Other (stated, no rule matched) |
| NCT02110563 | Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors,… | Phase 1 | terminated | Apr 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor Decision | Sponsor / business decision |
| NCT05820763 | Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple… | Phase 2 | withdrawn | Apr 20, 2023 | Washington University School of Medicine | Study sponsor decided to close study. | Sponsor / business decision |
| NCT02400242 | Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple… | Phase 1 | terminated | Mar 27, 2015 | Celgene | Lack of efficacy | Efficacy / futility |
| NCT02863991 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 11, 2016 | Jazz Pharmaceuticals | This study was terminated due to a change in corporate priorities. The decision to terminate the… | Safety / toxicity |
| NCT03777410 | Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma | — | terminated | Dec 17, 2018 | Travera Inc | Insufficient pace of enrollment due to changes in MM SOC practices | Enrollment / accrual |
| NCT04111107 | Precision Medicine for Patients With Identified Actionable Mutations | Phase 2 | terminated | Oct 1, 2019 | Wake Forest University Health Sciences | PI left the institution and site decided not to continue the study | Investigator |
| NCT05204160 | Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients… | Phase 2 | withdrawn | Jan 24, 2022 | Emory University | slow accrual | Enrollment / accrual |
| NCT03448978 | Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma | Phase 1 | terminated | Feb 28, 2018 | Cartesian Therapeutics | Phase 1 enrollment completed. Further clinical development terminated | Enrollment / accrual |
| NCT04352205 | Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With… | Phase 2 | terminated | Apr 20, 2020 | Emory University | Slow accrual | Enrollment / accrual |
| NCT05000450 | Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Allogene Therapeutics | Terminated (Halted Prematurely) | Other (stated, no rule matched) |
| NCT01670994 | QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 23, 2012 | Altor BioScience | Patient population did not benefit from single agent treatment. | Other (stated, no rule matched) |
| NCT04956302 | Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the… | Phase 1 | terminated | Jul 9, 2021 | Abdullah Khan | PI Decision | Other (stated, no rule matched) |
| NCT06232707 | A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care…(ALUMMINATE) | Phase 3 | withdrawn | Jan 31, 2024 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | N/A | terminated | Jan 22, 2021 | Centre Hospitalier Henri Duffaut - Avignon | Heart rate measurement error | Other (stated, no rule matched) |
| NCT04242121 | The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow… | — | terminated | Jan 27, 2020 | Ivan S Moiseev | poor recruitment | Enrollment / accrual |
| NCT06400264 | Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in… | Phase 2 | withdrawn | May 6, 2024 | National Cancer Institute (NCI) | No result will be reported- no patient accrued. Status Withdrawn: Study halted prematurely, prior… | Enrollment / accrual |
| NCT05950113 | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma | Phase 1 | withdrawn | Jul 18, 2023 | Jonsson Comprehensive Cancer Center | The study was withdrawn before opening | Other (stated, no rule matched) |
| NCT04407442 | Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or… | Phase 2 | terminated | May 29, 2020 | University of California, San Francisco | Slow enrollment and change in sponsor direction | Enrollment / accrual |
| NCT04685525 | Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT | N/A | withdrawn | Dec 28, 2020 | Case Comprehensive Cancer Center | Administrative decision | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 14, 2025source: clinicaltrials